CIK 0001006281 · Non-accelerated filer<br>Smaller reporting company
Protalix BioTherapeutics, Inc.
Sign in to watch- Ticker
- PLX
- Exchange
- NYSE
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 650643773
- Phone
- 201-696-9345
- Business address
- 2 UNIVERSITY PLAZA, SUITE 100, HACKENSACK, NJ, 07601
- Former names
- ORTHODONTIX INC, EMBASSY ACQUISITION CORP
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2009-10-19 | Aviezer David CEO and President | Sale | −150,000 | $9.43 | $1.4M | 0 |
| 2009-10-19 | Almon Einat Brill VP, Product Development | Sale | −38,320 | $9.43 | $361K | 0 |
| 2009-10-19 | Almon Einat Brill VP, Product Development | Option exercise | +93,954 | $0.40 | $37K | 0 |
| 2009-10-19 | Almon Einat Brill VP, Product Development | Shares withheld for taxes | −3,954 | $9.48 | $37K | 0 |
| 2009-10-19 | Almon Einat Brill VP, Product Development | Option exercise · Stock Options (Right to Buy) | −93,954 | 4,740 | ||
| 2009-10-19 | Shaaltiel Yoseph Executive VP, R&D | Sale | −43,120 | $9.43 | $407K | 1,263,754 |
| 2009-10-16 | Almon Einat Brill VP, Product Development | Sale | −23,680 | $9.39 | $222K | 0 |
| 2009-10-16 | Shaaltiel Yoseph Executive VP, R&D | Sale | −25,680 | $9.39 | $241K | 1,306,874 |
| 2009-10-16 | Maimon Yossi VP, Chief Financial Officer | Sale | −40,300 | $9.35 | $377K | 0 |
| 2009-10-16 | Maimon Yossi VP, Chief Financial Officer | Option exercise | +167,698 | $0.97 | $163K | 0 |
| 2009-10-16 | Maimon Yossi VP, Chief Financial Officer | Shares withheld for taxes | −17,698 | $9.21 | $163K | 0 |
| 2009-10-16 | Maimon Yossi VP, Chief Financial Officer | Option exercise · Stock Options (Right to Buy) | −167,698 | 223,733 | ||
| 2009-10-15 | Almon Einat Brill VP, Product Development | Sale | −28,000 | $9.39 | $263K | 0 |
| 2009-10-15 | Shaaltiel Yoseph Executive VP, R&D | Sale | −31,200 | $9.39 | $293K | 1,332,554 |
| 2009-10-15 | Maimon Yossi VP, Chief Financial Officer | Sale | −109,700 | $9.50 | $1.0M | 0 |
| 2009-09-10 | FROST PHILLIP MD ET AL 10% owner | Sale | −5,821 | $7.35 | $43K | 7,732,420 |
| 2009-09-10 | FROST PHILLIP MD ET AL 10% owner | Sale | −4,179 | $7.37 | $31K | 7,728,241 |
| 2009-09-10 | FROST PHILLIP MD ET AL 10% owner | Sale | −9,254 | $7.38 | $68K | 7,718,987 |
| 2009-09-10 | FROST PHILLIP MD ET AL 10% owner | Sale | −1,600 | $7.39 | $12K | 7,717,387 |
| 2009-09-10 | FROST PHILLIP MD ET AL 10% owner | Sale | −13,200 | $7.40 | $98K | 7,704,187 |
Page 11 of 33 · 654 trades